Incremental Value of Global Longitudinal Strain to Michigan Risk Score and Pulmonary Artery Pulsatility Index in Predicting Right Ventricular Failure Following Left Ventricular Assist Devices.

BACKGROUND: The incremental utility of right ventricular (RV) strain on predicting right ventricular failure (RVF) following left ventricular assist device (LVAD) implantation, beyond clinical and haemodynamic indices, is not clear. METHODS: Two hundred and forty-six (246) patients undergoing LVAD implantation, who had transthoracic echocardiograms pre and post LVAD, pulmonary artery pulsatility index (PAPI) measurements and Michigan risk score, were included. We analysed RV global longitudinal strain (GLS) using speckle tracking echocardiography. RVF following LVAD implantation was defined as the need for medical support for >14 days, or unplanned RV assist device insertion after LVAD implantation. RESULTS: Mean preoperative RV-GLS was -7.8±2.8%. Among all, 27% developed postoperative RVF. A classification and regression tree analysis identified preoperative Michigan risk score, PAPI and RV-GLS as important parameters in predicting postoperative RVF. Eighty per cent (80%) of patients with PAPI <2.1 developed postoperative RVF, while only 4% of patients with PAPI >6.8 developed RVF. For patients with a PAPI of 2.1-3.2, having baseline Michigan risk score >2 points conferred an 81% probability of subsequent RVF. For patients with a PAPI of 3.3-6.8, having baseline RV-GLS of -4.9% or better conferred an 86% probability of no subsequent RVF. The sensitivity and specificity of this algorithm for predicting postoperative RVF were 67% and 93%, respectively, with an area under the curve of 0.87. CONCLUSION: RV-GLS has an incremental role in predicting the development of RVF post-LVAD implantation, even after controlling for clinical and haemodynamic parameters.

Contemporary Outcomes of Pulmonary Valve Endocarditis: A 16-Year Single Centre Experience.

BACKGROUND: Limited data exist regarding the clinical characteristics and contemporary outcomes of patients with pulmonary valve (PoV) infective endocarditis (IE). METHODS: This is a retrospective cohort study of patients with a confirmed diagnosis of IE affecting the PoV at our centre between January 2002 and October 2018. Electronic medical records were reviewed to gather the clinical and echocardiographic variables. The population was subdivided according to risk factor profiles: group 1: miscellaneous risk factors; group 2: patients with congenital heart disease (CHD); and group 3: patients who inject drugs (PWID). The primary outcome was all-cause mortality. RESULTS: Out of 2,124 cases of IE during the study period, 24 (1.1%) patients had PoV IE. The majority of cases of PoV IE occurred in patients with prosthetic valves (54.2%). Coagulase-negative Staphylococci species were the most common micro-organisms. Seventy-five per cent (75%) of the patients required surgical management. The median follow-up was 2.8 years (interquartile range: 0.2-5.3 years). Patients with miscellaneous risk factors were older (p<0.01), and had higher rates of hypertension (p=0.01) and hyperlipidaemia (p=0.04). There was a statistically significant difference in survival between the groups (p=0.03), mainly driven by better outcomes of patients with CHD, compared to those with miscellaneous risk factors. CONCLUSIONS: In a contemporary 16-year series, a high proportion of patients with PoV IE required surgical management. Patients with PoV IE and CHD had better survival, compared to patients with miscellaneous risk factors at a median follow-up of 2.8 years.

Discordant cardiac inflammation between 18F-FDG PET and CMR in patients with cardiac sarcoidosis.

Current diagnostic criteria for cardiac sarcoidosis (CS) rely on non-invasive imaging tools including positron emission tomography (PET-CT) and cardiac magnetic resonance (CMR). The aim of this study was to assess the prevalence of discordant myocardial inflammation between PET-CT and CMR in patients with known cardiac sarcoidosis. We retrospectively identified patients with both 18F-FDG PET-CT and CMR who had histology-proven sarcoidosis (N = 148). Among these 25 (17%) had abnormal 18F-FDG metabolism with normal tissue characterization by CMR. Of these, 13 (9%) had the studies concomitantly within 180 days (median 5 days, IQR 1-31). During median follow up of 7 years, 3 (23%) deaths were documented. Although prospective studies are required to address the best imaging approach for cardiac inflammation, our observation that some patients with CS have evidence of disease activity on PET-CT, but not on limited CMR without mapping suggests that a negative limited CMR may not fully exclude CS.

Novel Multi-Parametric Mitral Annular Calcification Score Predicts Outcomes in Mitral Valve Dysfunction.

The objective of the study was to construct a multi-parametric mitral annular calcification (MAC) score using computed tomography (CT) features for prediction of outcomes in patients undergoing mitral valve surgery. We constructed a multi-parametric MAC score, which ranges between 2 and 12, and consists of Agatston calcium score (1 point: <1000 Agatston units (AU); 2 points: 1000-<3000 AU; 3 points: 3000-5000 AU; 4 points: >5000 AU), quantitative MAC circumferential angle (1 point: <90°; 2 points: 90-<180°; 3 points: 180-<270°; 4 points: 270-360°), involvement of trigones (1 point: 1 trigone; 2 points: both trigones), and 1 point each for myocardial infiltration and left ventricular outflow tract extension/involvement of aorto-mitral curtain. The association between MAC score and clinical outcomes was evaluated. The study cohort consisted of 334 patients undergoing mitral valve surgery (128 mitral valve repairs, 206 mitral valve replacements) between January 2011 and September 2019, who had both non-contrast gated CT scan and evidence of MAC. The mean age was 72 ± 11 years, with 58% of subjects being female. MAC score was a statistically significant predictor of total operation time (P<0.001), cross-clamp time (P = 0.001) and in-hospital complications (P = 0.003). Additionally, MAC score was a significant predictor of time to all-cause death (P = 0.046). A novel multi-parametric score based on CT features allowed systematic assessment of MAC, and predicted clinical outcomes in patients with mitral valve dysfunction undergoing mitral valve surgery.

Impact of left atrial strain mechanics on exercise intolerance and need for septal reduction therapy in hypertrophic cardiomyopathy.

AIMS: We sought to assess the relationship between left atrial (LA) strain mechanics and exercise intolerance, and to evaluate the prognostic impact of LA strain mechanics on clinical deterioration necessitating septal reduction therapy in hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: Consecutive HCM patients who underwent exercise stress echocardiography and cardiopulmonary exercise testing on the same day between October 2015 and April 2019 were enrolled prospectively. LA strain mechanics were analysed using speckle tracking echocardiography. LA stiffness was calculated as the ratio of E/e' ratio to LA reservoir strain. The study cohort was divided into four groups based on the quartile of percent-predicted peak VO2, and exercise intolerance was defined as the lowest quartile (≤51%). Of 532 patients studied (mean age: 51 ± 15 years, 42% female), 138 patients demonstrated exercise intolerance. As exercise capacity worsened, LA strain mechanics worsened along a continuum (P < 0.001). LA contractile strain with a cut-off of -13.9% was optimal at identifying exercise intolerance. On multivariable analysis, worse LA contractile strain was an independent predictor for exercise intolerance (P = 0.002). Of patients with left ventricular outflow tract obstruction, patients with LA stiffness worse than the median value (≥0.41) were significantly more likely to require septal reduction therapy than those with better LA stiffness (P = 0.026). CONCLUSION: Worse LA contractile strain was an independent predictor for exercise intolerance in HCM. Patients with worse LA stiffness had a higher probability of clinical deterioration necessitating septal reduction therapy.

Impact of Frailty and Mitral Valve Surgery on Outcomes of Severe Mitral Stenosis Due to Mitral Annular Calcification.

We sought to evaluate the outcomes of patients with severe mitral stenosis (MS) resulting from mitral annular calcification and assessed the prognostic impact of co-morbidities and frailty in guiding management. Among 6,915 patients with calcific MS who underwent echocardiography between January 2011 and March 2020, a total of 283 patients with severe calcific MS were retrospectively enrolled. We calculated the Charlson co-morbidity index (CCI). Frailty was scored from 0 to 3 points, with 1 point each assigned for reduced hemoglobin, reduced albumin, and inactivity. The primary end point was all-cause death. The mean age was 72 ± 11 years. The mean mitral valve (MV) area was 1.1 ± 0.4 cm2, and the mean transmitral gradient was 12 ± 4 mm Hg. Although 33% of the patients underwent MV intervention, 67% were conservatively managed. During a median follow-up of 360 days, 35% died. Patients who underwent MV intervention had an improved prognosis compared with those who were treated conservatively, even after propensity score matching. On multivariate Cox regression analysis, higher CCI (hazard ratio [HR] 1.20, 95% confidence interval [CI] 1.04 to 1.38, p = 0.011) and frailty score (HR 1.58, 95% CI 1.12 to 2.23, p = 0.01) were predictors of all-cause mortality, and MV intervention (HR 0.45, 95% CI 0.25 to 0.83, p = 0.011) and angiotensin converting enzyme inhibitor/angiotensin receptor blocker use (HR 0.39, 95% CI 0.20 to 0.79, p = 0.009) were associated with an improved prognosis. In conclusion, patients with severe calcific MS were often frail with multiple co-morbidities and were often managed conservatively. Higher CCI and worse frailty were associated with worse prognosis, regardless of the treatment strategy. MV intervention for select patients was associated with improved prognosis.

Mixoma ventricular izquierdo / Left ventricular myxoma

Resumen Introducción: El mixoma es un tumor benigno con prevalencia de 0,01 a 0,03% en la población, principalmente de presentación esporádica y con predilección por la aurícula izquierda seguido por la aurícula derecha. La localización en los ventrículos es considerablemente más infrecuente y la sintomatología varía según el lugar de origen. Con la presentación de este caso se hará énfasis en: las manifestaciones clínicas, el diagnóstico y el tratamiento del mixoma. Objetivo: Presentar un caso clínico de mixoma ventricular izquierdo en la Fundación Santa Fe de Bogotá de un hombre de 50 años sin antecedentes de importancia, con disnea de esfuerzos y dolor retroesternal de dos meses de evolución. El ecocardiograma transtorácico, la resonancia nuclear magnética, y el cateterismo cardiaco, evidenciaron una masa en la región posteriory medial del ápex, por lo que se realizó la resección quirúrgica del tumor. Posteriormente, el estudio anatomopatológico confirmó el diagnóstico inicial dado por las imágenes. El pacientetuvo una evolución favorable y fue dado de alta seis días después con resultados satisfactorios. Discusión: Es más frecuente en el sexo femenino y la edad adulta, aunque se reportan casos entodas las edades. La localización de los mixomas es de 75-80% en la aurícula izquierda, 20% enla aurícula derecha, 3% en el ventrículo izquierdo, y 3% en el ventrículo derecho. Las manifestaciones se evidencian con síntomas constitucionales (74%), disnea (45%) y embolismo (41%). Conclusión: Las neoplasias cardiacas son infrecuentes siendo el mixoma, el tumor benigno más común del corazón. El diagnóstico puede ser sugerido por los síntomas, aunque es usual encontrar un examen físico normal. Se diagnóstica con el ecocardiograma transtorácico, la tomografía axial computarizada y la resonancia nuclear magnética. El tratamiento es quirúrgico, siendo seguro, efectivo y considerado curativo en la mayoría de las resecciones, con una tasa de supervivencia a 5 años del 83%.

Abstract Introduction: Myxomas are a benign tumour with a prevalence of 0,01 to 0,03%, mostly of sporadic presentation and with a preference for the left atrium, followed by the right atrium. Their location in the ventricles is considerably more infrequent and their symptomatology varies depending on their placement. With the presentation of this case focus will lie on clinical manifestations, diagnosis and treatment of myxomas. Motivation: To present a clinical case of left ventricular myxoma in the Fundación Santa Fe de Bogotá in a 50 year-old male without relevant medical conditions, with exertional dyspnea and restrosternal pain over the last two months. The transthoracic echocardiogram, magnetic resonance and cardiac catheterization evidenced a mass in the anterior and medial regions of the apex, therefore a surgical resection of the tumour was carried out. Later on the histological analysis confirmed the initial imaging diagnosis. The patient presented a favourable evolution and was discharged six days later with positive results. Discussion: It is more frequent in females and in adults, though cases are reported in all ages. Location of myxomas is 75-80% in the left atrium, 20% in the right atrium, 3% in the left ventricle and 3% in the right ventricle. Manifestations are evidenced with constitutional symptoms (74%), dyspnea (45%) and embolism (41%). Conclusion: Cardiac neoplasms are infrequent, myxomas being the most common benign heart tumours. The diagnosis can be suggested by the symptoms, though it is usual to encounter a normal physical examination. It is diagnosed with transthoracic echocardiogram, computerised axial tomography and magnetic resonance. Treatment is surgical, being safe, effective and considered curative in most resections, with a survival rate after 5 years of 83%.